Ligand trap for the activin type IIA receptor. The long-sought drug to overcome the calcification paradox in CKD?

详细信息    查看全文

• 作者：Anja Verhulst¹ ; Pieter Evenepoel² ; ³ ; Patrick C. D'Haese¹ ; ^{patrick.dhaese@uantwerpen.be}
• 刊名：Kidney International
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：91
• 期：1
• 页码：11-13
• 全文大小：894 K
• 卷排序：91

文摘

The chronic kidney disease–mineral and bone disorder syndrome illustrates the association between a disturbed physiological bone turnover/mineralization and pathologic vascular mineralization; the so-called calcification paradox. This implies that treatments aimed at curing bone disorders might have serious implications for cardiovascular health and vice versa. Hence, there is an urgent need for treatments that are able to break through this cross-talk. Hereto, compounds such as those interfering with activin type IIA receptor signaling and acting upstream of the Wnt–β-catenin pathway are of particular interest.